S&P Futures
4,118.50 -6.00 (-0.15%) Dow Futures
32,711.00 -26.00 (-0.08%) Nasdaq Futures
12,997.25 -34.25 (-0.26%) Russell 2000 Futures
1,911.20 -3.40 (-0.18%) Crude Oil
89.48 -1.02 (-1.13%) Gold
1,804.20 -8.10 (-0.45%)
ACADIA Pharmaceuticals Inc. (ACAD)
After hours:
Chart Events
Performance Outlook
| Previous Close | 16.62 |
| Open | 16.60 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 900 |
| Day's Range | 15.21 - 16.83 |
| 52 Week Range | 12.24 - 28.06 |
| Volume | |
| Avg. Volume | 2,687,845 |
| Market Cap | 2.618B |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.33 |
| Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.13 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ACAD
Related Research
- ACADIA Pharmaceuticals Inc.Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic Moat2 days agoMorningstar
- Benzinga
Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) non-opioid painkiller. The company scrapped the ACP-044 program after evaluating the final phase 2 data on bunion removal patients. Initial data announced in April showed that the primary endpoint of pain intensity was not met. Rival Vertex boasted a mid-phase win for a similar candidate. Acadia has also discontinued ACP-319, which w
- Zacks
Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates
Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
- Zacks
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
